Study · Randomized controlled trial · 2019

3 results

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Minisola S, Marin F, Marin F, Kendler DL, Geusens P, Zerbini CAF, Russo LA, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Moericke R and 4 more

Show all authors

Bagur A, Lakatos P, López-Romero P, Body JJ

Archives of osteoporosis18 Jan 2019Cited by 6 (Europe PMC)

PMID30659410DOI10.1007/s11657-019-0561-xPepBankPUB-30659410

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide reduced serum 25-hydroxy-vitamin D compared with risedronate at month 6.
In plain wordsIn women with osteoporosis, teriparatide lowered vitamin D levels compared with risedronate at month 6.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum 25-hydroxy-vitamin D
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Serum 25(OH)D
24.5 ng/mL
teriparatide group, month 6
Serum 25(OH)D
32.2 ng/mL
risedronate group, month 6
Decrease in serum 25(OH)D
≈ 23%
teriparatide group, month 6
Source sentences
Summary
At month 6, the mean serum 25(OH)D concentration decreased in teriparatide-treated patients to 24.5 ng/mL (by approximately 23%) but remained relatively constant in risedronate-treated patients (32.2 ng/mL) (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with established osteoporosis received subcutaneous daily teriparatide 20 μg or oral weekly risedronate 35 mg, with concomitant 500-1000 mg of elemental calcium and 400-800 IU/day of vitamin D supplements.
Report a problemFND-3065941001
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, vitamin D insufficiency was more frequent with teriparatide than risedronate at month 6.
In plain wordsIn women with osteoporosis, vitamin D insufficiency was more frequent with teriparatide than risedronate at month 6.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVitamin D insufficiency proportion
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Proportion 25(OH)D insufficient
26.7%
teriparatide group, month 6
Proportion 25(OH)D insufficient
5.6%
risedronate group, month 6
Source sentences
Summary
Proportions of 25(OH)D insufficient patients at month 6 were 26.7% and 5.6%, respectively (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with established osteoporosis received subcutaneous daily teriparatide 20 μg or oral weekly risedronate 35 mg, with concomitant 500-1000 mg of elemental calcium and 400-800 IU/day of vitamin D supplements.
Report a problemFND-3065941002

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, fracture risk reduction with teriparatide versus risedronate did not differ significantly by baseline vitamin D sufficiency.
In plain wordsIn women with osteoporosis, baseline vitamin D status did not significantly change fracture risk reduction with teriparatide versus risedronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFracture treatment interaction with vitamin D status
Study
n: not reported in source
Comparator
Risedronate
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The risk reduction with teriparatide versus risedronate for any of the fracture endpoints did not significantly differ between subgroups by 25(OH)D sufficiency status at baseline, with nonsignificant (p > 0.1) treatment-by-25(OH)D interactions in all fracture analyses.
1 context sentence(design, population, supporting numbers)
Summary · context
Postmenopausal women with established osteoporosis received subcutaneous daily teriparatide 20 μg or oral weekly risedronate 35 mg, with concomitant 500-1000 mg of elemental calcium and 400-800 IU/day of vitamin D supplements.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3065941003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01709110

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Eli Lilly and Companyn = 1,366Oct 2012 to Jul 2016

Postmenopausal Osteoporosis

Trial page ClinicalTrials.govUpdated 23 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.